- Categories:About Us
- Time of issue:2019-05-24 00:00:00
Founded in March 2017, IASO BIO is engaged in the development and industrialization of tumor cell immunotherapy drugs. Launched in Nanjing Biotech and Pharmaceutical Valley, the company has a total of 7,000㎡ of R&D platform and GMP pilot platform, and almost 10,000㎡ of commercial space in Nanjing. It also has a 1,750㎡ R&D platform in Zhangjiang Hi-tech Park ( Shanghai) and a global R&D center of approximately 57,000 square meters under construction in Shanghai Pilot Free Trade Zone. The company currently employs 350 staff.
IASO BIO specializes in the development of innovative hematological tumor cell drugs and antibody drugs, and is now expanding its focus to solid tumors and autoimmune diseases. Its own fully human antibody platform provides high-quality antibody sequences for the development of cell drugs and antibody drugs. The company’s autologous CAR-T product, CT103A, targeting BCMA, has entered Phase II clinical trial. Currently the company has more than ten pipeline products initiated by researchers which are undergoing clinical trials.